Episode 839: Medicus Pharma ($MDCX) Chairman on Expanding SkinJect, Teverelix Tests

This interview is disseminated on behalf of Medicus Pharma Ltd.

With Phase 2 studies moving forward across its clinical programs, Medicus Pharma (NASDAQ: MDCX) is also planning to evaluate the use of its SkinJect anti-skin cancer patch to combat Gorlin Syndrome, a rare genetic disorder, as well as Teverelix for the potential treatment of endometriosis.

Executive Chairman and CEO Dr. Raza Bokhari shares more details about the company’s FDA application to test SkinJect in Gorlin Syndrome patients, its genomics-enabled clinical trial in Abu Dhabi for Teverelix’s use in endometriosis, and anticipated growth milestones, including potential strategic partnerships.

Learn more about Medicus Pharma: https://medicuspharma.com/

Watch the full YouTube interview here: https://youtu.be/v_ZhrQE2DFM
And follow us to stay updated: https://www.youtube.com/GlobalOneMedia